Page 51 - Demo

FOLFIRINOX reintroduction in pancreatic cancer493a second treatment episode (minimum one cycle) with FOLFIRINOX after a minimum of 3 months (90 days) without any systemic treatment (therapy-free interval). Treatment duration intervals were calculated from start until stop date of the specific regimen. When patients continued fluorouracil-based therapy in a monotherapy or doublet regimen with oxaliplatin/irinotecan within 90 days after FOLFIRINOX, the stop date of the last agent in this regimen was used as the stop date of the FOLFIRINOX treatment. Retreatment with fluorouracil and oxaliplatin/irinotecan in a monotherapy or doublet regimen after a 3 months therapy-free interval was not classified as FOLFIRINOX reintroduction. Clinical benefit was defined as a documented radiologic complete or partial response (CR, PR) or stable disease (SD). Statistical AnalysisData in this study were analyzed using SPSS statistics 28 (IBM). OS was defined as the interval from diagnosis until death from any cause or otherwise noted, censored at last follow up date, updated on February 1, 2022. PFS was defined from start of reintroduction of FOLFIRINOX to documented progression. Data on progression were not available for all patients. In patients without documented progression of FOLFIRINOX reintroduction (n=36), time to progression was censored at time of last visit. However, several of these patients deceased within 30 days after the last visit or deceased (in the hospital) on the same day as the last hospital visit. Sensitivity analysis was performed with death within 30 days after the last hospital visit defined as a progression event. Median OS and PFS were analyzed using Kaplan Meier curves. A log rank test (Mantel-Cox) was used to compare OS differences in treatment groups. In addition, patients who deceased or stopped treatment within 30 days after FOLFIRINOX reintroduction were compared with other patients with reintroduction.ResultsFirst line systemic therapyA total of 2092 patients who received systemic treatment with palliative intent for PDAC were included. Median age was 65 years (range 25-87). The majority of patients had distant metastases at time of diagnosis (74.7%) and the primary tumor was histologically or cytologically confirmed in 93% (table 1). Patients in this cohort